A Study of AZD8233 in Participants With Dyslipidemia

Key Inclusion Criteria: * Male or female. * Participant must be 18 to 75 years of age. * Body mass index between 19 and 40 kg/m2. * Participants who have a fasting LDL-C ≥ 70 mg/dL but \< 190 mg/dL. * Have fasting triglycerides \< 400 mg/dL. * Should be receiving moderate- or high-intensity statin therapy. * Should be on stable medication for ≥ 3 months prior to screening with no planned medication or dose change during study participation. The exception to this restriction is for fenofibrate; if the participant is receiving fenofibrate, the therapy must be stable for at least 6 weeks prior to randomization at a dose that is appropriate for the duration of the study in the judgement of the Investigator. Other fibrate therapy (and derivatives) are prohibited. Key Exclusion Criteria: * Estimated glomerular filtration rate \< 40 mL/min/1.73m2 CKD-EPI. * Any uncontrolled or serious disease, or any medical dysfunction or surgical condition that, in the opinion of the Investigator, may either interfere with participation in the clinical study and/or put the participant at significant risk. * Poorly controlled type 2 diabetes mellitus, defined as HbA1c \> 10% at Visit 1. * Acute ischaemic cardiovascular event in the last 12 months prior to randomization. * Heart failure with New York Heart Association (NYHA) Class III-IV. * High-risk of bleeding as judged by the Investigator. * Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal * Carcinoma in-situ, or Stage 1 prostate carcinoma) within the last 10 years. * LDL or plasma apheresis within 12 months prior to randomization. * Uncontrolled hypertension defined as average supine SBP \> 160 mmHg or DBP \> 90 mmHg at Visit 1 or Visit 3. * Heart rate after 10 minutes supine rest \< 50 bpm or \> 100 bpm. * Any laboratory values with the following deviations at Screening: * Positive result on screening for hepatitis B, hepatitis C or HIV. * ALT \> 1.5 × ULN. * AST \> 1.5 × ULN. * TBL \> ULN. * ALP \> 1.5 × ULN. * WBC \< LLN. * Haemoglobin \< 12 g/dL in men or \< 11 g/dL in women. * Platelet count ≤ LLN. * aPTT \> ULN and PT \> ULN. * UACR \> 11.3 mg/mmol (100 mg/g). * UPCR \> 300 mg/g. * Any clinically important abnormalities in rhythm, conduction or morphology of the resting ECG and any clinically important abnormalities in the 12-lead ECG as judged by the Investigator. * Mipomersen, or lomitapide within 12 months prior to randomization. * Previous administration of AZD8233/AZD6615. * Previous administration of PCSK9 inhibition treatment. * Participation in another clinical study with a study intervention administered in the last 3 months prior to randomization or 5 half-lives from last dose to first administration of study intervention, whichever is the longest.